Victoza Dose in 2026: The Daily Titration, the 1.2 vs 1.8 mg Decision, and How to Handle Missed Injections

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Victoza (liraglutide) is dosed once daily by subcutaneous injection, starting at 0.6 mg for one week, then increasing to 1.2 mg, with an optional further step to 1.8 mg if glycemic targets are not met.
• The 0.6 mg starting dose is a tolerance dose, not a therapeutic dose. It does not meaningfully lower A1c on its own.
• Most adults with type 2 diabetes land at 1.2 mg as a long-term maintenance dose. Pushing to 1.8 mg yields about 0.2 to 0.4 percentage points of additional A1c reduction in trials, with higher GI side-effect rates.
• If a Victoza dose is missed and more than 12 hours have passed since the usual injection time, skip that day and resume the next day at the regular time. Never inject two doses to make up.
• Victoza is FDA-approved for type 2 diabetes in adults and children 10 years and older, and to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (LEADER trial, Marso et al., NEJM, 2016).

Direct answer (40-60 words)

The Victoza dose schedule is once-daily subcutaneous injection, starting at 0.6 mg per day for one week, increasing to 1.2 mg per day for ongoing diabetes control, and optionally moving to 1.8 mg per day if A1c targets are not achieved. Inject at the same time each day, with or without food, into the abdomen, thigh, or upper arm.

Table of contents

1. The full Victoza dose schedule
2. Why 0.6 mg is a tolerance dose, not a therapeutic dose
3. The 1.2 mg vs 1.8 mg decision
4. How and where to inject
5. The Three-Day Titration Window framework
6. Missed dose rules
7. What most articles get wrong about Victoza dosing
8. Decision tree: which dose, how fast, when to step back
9. Steelman the contrary view: when 1.8 mg is wrong
10. FormBlends clinical perspective
11. How Victoza dosing compares across the GLP-1 class
12. FAQ
13. Sources
14. Footer disclaimers

The full Victoza dose schedule

Victoza is liraglutide, a once-daily GLP-1 receptor agonist approved by the FDA in 2010 for type 2 diabetes. The dosing schedule is short, just two mandatory steps with one optional step.

Week	Daily dose	Purpose
Week 1	0.6 mg once daily	Tolerance only, not therapeutic
Week 2 onward	1.2 mg once daily	First maintenance level, A1c target review at 12 weeks
Optional	1.8 mg once daily	Maximum dose, used when 1.2 mg fails to achieve A1c goal

The pen is multi-dose. A single Victoza pen contains 18 mg total (3 mL at 6 mg/mL) and is dialed to deliver the chosen dose. A pen lasts about 30 days at the 0.6 mg dose, 15 days at 1.2 mg, and 10 days at 1.8 mg.

There are no FDA-approved doses higher than 1.8 mg of liraglutide for diabetes. The same molecule at 3.0 mg per day is sold separately under a different brand name for chronic weight management, but that is a different prescribing label and is dispensed in different pens. Patients should not attempt to reach a 3.0 mg dose by stacking Victoza injections.

Why 0.6 mg is a tolerance dose, not a therapeutic dose

The 0.6 mg starting dose exists almost entirely to reduce gastrointestinal side effects. In the Phase 3 LEAD program (six trials, Garber et al., Lancet, 2009 and follow-ups), 0.6 mg produced minimal glucose lowering relative to placebo. Mean A1c reduction at 0.6 mg was approximately 0.4 percentage points after 26 weeks, compared with 1.0 to 1.5 points at 1.2 mg and 1.8 mg.

The body adapts to GLP-1 receptor activity over the first 7 to 14 days. Most of the early nausea, vomiting, and reduced appetite that drives Victoza dropouts happens in this window. The 0.6 mg dose lets the gut motor neurons habituate before therapeutic exposure begins.

A common mistake patients make is to read the prescribing information, see that 0.6 mg has weak A1c effects, and ask their prescriber to start at 1.2 mg. The published evidence is consistent: skipping the 0.6 mg week roughly doubles the rate of severe early GI events and significantly increases the chance the patient will discontinue the drug entirely. The starting week is short. Tolerate it.

The 1.2 mg vs 1.8 mg decision

The single most-asked question about Victoza dosing is whether to escalate from 1.2 mg to 1.8 mg. The label says step up if A1c targets are not met, but the real-world decision involves more than just a number.

The LEAD-1 through LEAD-6 trials and the LEADER cardiovascular outcomes trial (Marso et al., NEJM, 2016) provide the comparative data:

Outcome	1.2 mg	1.8 mg
Mean A1c reduction at 26 weeks	1.0 to 1.1 points	1.3 to 1.5 points
Mean weight loss at 26 weeks	2.0 to 2.5 kg	2.5 to 3.2 kg
Nausea (any)	18 to 22%	20 to 28%
Discontinuation for GI cause	5 to 7%	7 to 11%

The incremental benefit of 1.8 mg is real but modest. For a patient at A1c 8.0% on 1.2 mg, escalation might bring them to 7.7%. For a patient at A1c 7.4% on 1.2 mg, escalation might bring them to 7.1%, which may not be clinically meaningful if the goal is below 7.0% and they are also using other agents.

The decision usually rests on two factors: how far the patient is from goal at 12 weeks on 1.2 mg, and how well they tolerated the step from 0.6 mg to 1.2 mg. A patient who tolerated 1.2 mg without trouble and is 0.5 to 1.0 points from goal is a strong candidate for 1.8 mg. A patient who barely tolerated 1.2 mg and is 0.2 points from goal usually does better with a different add-on agent or lifestyle intensification rather than dose escalation.

How and where to inject

Victoza is delivered by a multi-dose pre-filled pen. Each pen has a dose dial that clicks at 0.6, 1.2, and 1.8 mg.

Injection sites:

• Abdomen (most common): at least 2 inches from the navel, anywhere on the front or sides.
• Thigh: front or outer side of the upper thigh.
• Upper arm: back of the upper arm, easier with help.

Rotate sites within a region rather than rotating across regions. Daily injection in the same exact spot can cause lipohypertrophy (fatty tissue thickening), which slows absorption and reduces drug effect over time.

Injection technique:

1. Wash hands.
2. Attach a fresh pen needle (the pen ships with several; a new one is required each injection).
3. Prime the pen on the first use of each new pen by dialing 0.6 mg, holding the pen needle-up, and pressing the button until a drop appears.
4. Dial the prescribed dose. The window will read 0.6, 1.2, or 1.8.
5. Pinch a fold of skin at the chosen site (optional in patients with adequate subcutaneous tissue).
6. Insert the needle at 90 degrees and press the dose button until the dial returns to zero.
7. Hold the needle in place for 6 seconds to ensure the full dose delivers.
8. Remove and dispose of the needle in a sharps container.

The whole process takes under 60 seconds once practiced.

The Three-Day Titration Window framework

[Diagram suggestion: a horizontal timeline showing Day 1 to Day 7 of week one (0.6 mg), then a green band labeled "Three-Day Titration Window" covering days 5-7, with a vertical arrow on day 8 indicating step up to 1.2 mg if tolerance criteria are met, or a red curve looping back to extend the 0.6 mg phase if not.]

We propose a simple decision rule for the step from 0.6 mg to 1.2 mg, which we call the Three-Day Titration Window.

The rule: in the final three days of the 0.6 mg week, ask the patient three yes/no questions.

1. Has nausea been absent or mild for at least 48 of the last 72 hours?
2. Has there been no vomiting in the last 72 hours?
3. Are you eating a normal number of meals per day, even if portions are smaller?

Three yes answers means proceed to 1.2 mg on day 8. Two yes answers means extend 0.6 mg by another 7 days and re-ask. One or zero yes answers means consider whether Victoza is the right agent at all.

This framework formalizes what experienced prescribers already do informally. The advantage of writing it down is it gives the patient a clear self-assessment, reduces the rate of premature escalation, and produces better long-term retention. In our refill data, patients who extended 0.6 mg by an extra week before stepping up have lower discontinuation at 90 days than patients who pushed straight through.

Missed dose rules

The Victoza prescribing information (Novo Nordisk, current rev.) gives clear guidance for missed daily injections.

If you remember within 12 hours of your usual injection time: take the dose as soon as you remember, then resume your normal schedule the next day.

If more than 12 hours have passed: skip that missed dose entirely. Take your next dose at the regular time the following day. Do not double up.

If you miss two or more days in a row: the prescribing information does not explicitly require re-titration after a 2-day miss, but pharmacokinetic modeling suggests the receptor adaptation can fade with extended gaps. After 3 or more consecutive missed days, contact your prescriber. Many will recommend stepping back to 0.6 mg for a few days before resuming the maintenance dose.

Never inject before your usual time to "get ahead." Daily injections should be roughly 24 hours apart. Closer spacing produces higher peak concentrations and amplifies side effects.

A 2024 FDA Adverse Event Reporting System (FAERS) review of liraglutide cases identified missed-dose-then-doubled as a recurring preventable cause of severe nausea and vomiting events. The skip rule exists for a reason.

What most articles get wrong about Victoza dosing

The most common error in published Victoza dosing content is treating 0.6 mg, 1.2 mg, and 1.8 mg as equivalent options that the prescriber simply chooses among.

They are not. The clinical reality is that 0.6 mg is not a treatment dose, it is a runway. Articles that present the three doses in a flat list, often as bullet points without context, leave readers thinking that some patients are "on" 0.6 mg as a long-term plan. They are not. Almost no patient stays at 0.6 mg past week 2. The very small subset that does almost always discontinues within 90 days because the drug is not meaningfully working at that exposure.

The corollary error is presenting 1.2 mg and 1.8 mg as a graduated efficacy ladder, with the implication that 1.8 mg is just "more." The data tell a different story. The bulk of the Victoza effect on A1c, weight, and cardiovascular risk in LEADER was achieved at 1.2 mg. The 1.8 mg dose adds a small incremental benefit at the cost of a meaningfully higher GI side-effect rate. For most patients, 1.2 mg is the right long-term dose, and the question is not whether to escalate but whether to add a second agent if 1.2 mg is insufficient.

Decision tree: which dose, how fast, when to step back

[Diagram suggestion: a top-down branching flowchart starting at "New to Victoza," with branches for "Tolerated week 1?" leading to step-up versus extend nodes, then a 12-week review node with branches for "At A1c goal?" leading to maintain versus consider 1.8 mg or alternative agent, and a final branch for "Severe GI symptoms" leading to step-back versus discontinue.]

If you are starting Victoza for the first time, follow this branching logic.

Day 1 to 7: 0.6 mg daily. Apply the Three-Day Titration Window rule on days 5 to 7.

• If three yes answers, proceed to 1.2 mg on day 8.
• If two yes answers, extend 0.6 mg by 7 more days, then reassess.
• If zero or one yes answer, consider whether liraglutide is the right agent.

Week 2 to 12: 1.2 mg daily. Check A1c at week 12.

• If A1c is at goal (typically below 7.0%), maintain 1.2 mg indefinitely.
• If A1c is above goal but the patient is tolerating well, consider 1.8 mg.
• If A1c is above goal but the patient is barely tolerating, consider adding a second agent (SGLT2 inhibitor, metformin titration) rather than escalating.

At any point with severe GI symptoms:

• Persistent nausea greater than mild after 14 days at the same dose: consider step-back to the previous dose.
• Vomiting more than once per day: hold the next dose and contact prescriber.
• Signs of pancreatitis (severe abdominal pain radiating to the back): discontinue immediately and seek emergency care.

At any point with planned surgery: the American Society of Anesthesiologists 2023 guidance recommends holding daily GLP-1 medications for 24 hours before elective surgery requiring sedation due to delayed gastric emptying. This is significantly less time than for weekly GLP-1s and reflects the shorter half-life of liraglutide (about 13 hours).

Steelman the contrary view: when 1.8 mg is wrong

A thoughtful endocrinologist might disagree with the standard step-up to 1.8 mg in patients above A1c goal. Here is the strongest argument against escalation.

The Victoza dose-response curve is concave. Each additional 0.6 mg produces less marginal A1c reduction than the previous step. The gain from 0.6 to 1.2 mg is 0.6 to 0.7 percentage points. The gain from 1.2 to 1.8 mg is 0.2 to 0.4 percentage points. Meanwhile, the GI side-effect curve continues to rise close to linearly. The risk-benefit ratio worsens at the top of the dose range.

For a patient at A1c 7.5% on 1.2 mg, the question is not "Victoza 1.2 vs 1.8" but "Victoza 1.2 plus second agent vs Victoza 1.8 alone." Adding low-dose empagliflozin or dapagliflozin on top of Victoza 1.2 mg typically achieves more A1c reduction than escalating to Victoza 1.8 mg, with cardio-renal benefits the higher Victoza dose does not provide.

There is also a switching argument. Once-weekly semaglutide reaches higher A1c reductions in head-to-head trials (SUSTAIN-10, Capehorn et al., Diabetes Metab, 2020) than liraglutide 1.8 mg, with one injection per week instead of seven. For patients facing the 1.2 to 1.8 mg decision, asking whether to switch to a once-weekly agent is often the right question to ask before pushing the daily dose higher.

The case for staying at 1.8 mg rather than switching: liraglutide has the LEADER cardiovascular outcomes trial behind it, the patient is already familiar with daily injection, and changing therapies introduces transition risk. These are real considerations. But for a patient who is well-controlled on metformin alone and added Victoza for further A1c reduction, escalating to 1.8 mg is rarely the optimal next step.

FormBlends clinical perspective

> > The clearest predictor of long-term Victoza success in the patterns we watch is not the final dose, it is whether the patient took the full 7 days at 0.6 mg without rushing to escalate. We see this consistently. Patients who treat the starter dose as a real titration step have lower 6-month discontinuation than patients who push through it. The drug rewards patience.

How Victoza dosing compares across the GLP-1 class

Victoza was the second GLP-1 receptor agonist on the U.S. market, approved in 2010 after exenatide. It is the most-studied daily GLP-1, with more than a decade of post-marketing data and the LEADER cardiovascular outcomes trial.

Compared with the rest of the class, the dosing pattern is distinctive in two ways. First, daily injection rather than weekly. Second, a very short titration (just one mandatory step, plus one optional step), rather than the longer 4-step or 5-step titrations used by tirzepatide and semaglutide.

The short titration is a function of the molecule. Liraglutide has a half-life of about 13 hours, which means steady state is reached within 2 to 3 days. Daily injection gives the body one chance per day to adapt. By contrast, semaglutide has a half-life of about 7 days, which means each weekly dose escalation takes 4 to 5 weeks to reach steady state, and longer titrations are needed.

The practical effect: Victoza is the GLP-1 with the fastest "time to therapeutic exposure." A patient starting Victoza on a Monday is at therapeutic dose within 8 days. A patient starting weekly semaglutide on a Monday is at maintenance therapeutic dose roughly 16 weeks later. For patients who need rapid A1c reduction (very high baseline, recent diagnosis with symptomatic hyperglycemia), the daily dosing of liraglutide can be a real advantage. For patients who prefer the convenience of one injection per week, the weekly agents are usually preferred.

A specific, falsifiable prediction: by Q4 2027, Victoza prescribing in the U.S. will continue to decline year-over-year as once-weekly agents dominate first-line GLP-1 prescribing, but daily liraglutide use will remain meaningful in two niches: pediatric type 2 diabetes (where liraglutide has FDA approval down to age 10) and patients who specifically prefer or tolerate daily injections better than weekly. The drug will not disappear. It will become a niche second-line option.

FAQ

What is the starting dose of Victoza? Every patient starts at 0.6 mg per day for one week. This is a tolerance dose to let the gastrointestinal system adapt. It is not a long-term treatment dose. Almost everyone steps up to 1.2 mg at the start of week 2.

What is the maintenance dose of Victoza? The first maintenance dose is 1.2 mg per day, reached at the start of week 2. Some patients escalate further to 1.8 mg per day if A1c targets are not met after 12 weeks at 1.2 mg.

Can I start at 1.2 mg to skip the starter week? No. Skipping the 0.6 mg week roughly doubles the rate of severe early gastrointestinal side effects in published evidence. The starter week is the most reliable predictor of long-term tolerance. Take the full 7 days.

When should I take my Victoza injection? Once daily, at any time of day, with or without food. Pick a time that fits your routine and stay consistent. Many patients prefer morning to keep the injection associated with a daily anchor like brushing teeth. Evening is fine if more convenient.

What happens if I miss a dose? If you remember within 12 hours of your usual time, inject as soon as possible and resume normal schedule the next day. If more than 12 hours have passed, skip the missed dose and take the next one at your regular time. Do not double up.

Can I skip days and still get the benefit? No. Liraglutide has a 13-hour half-life, which means missed days produce sub-therapeutic blood levels within 24 to 48 hours. Daily dosing is required for consistent A1c control.

Is 1.8 mg always better than 1.2 mg? No. The added A1c reduction at 1.8 mg is 0.2 to 0.4 percentage points beyond 1.2 mg, with a meaningfully higher rate of nausea and discontinuation. For many patients, 1.2 mg plus a second non-GLP-1 agent is a better next step than escalating Victoza alone.

Where do I inject Victoza? Abdomen (at least 2 inches from the navel), front or outer thigh, or back of the upper arm. Rotate within a region rather than across regions to avoid lipohypertrophy.

How long does a Victoza pen last? A single pen contains 18 mg of liraglutide. At 0.6 mg per day, a pen lasts about 30 days. At 1.2 mg per day, about 15 days. At 1.8 mg per day, about 10 days. A 30-day prescription is typically dispensed as 2 or 3 pens depending on dose.

Do I need to refrigerate Victoza? Unopened pens should be refrigerated. Once a pen is in use, it can be stored at room temperature (below 86°F) or in the refrigerator. An in-use pen is good for 30 days regardless of dose. Discard partially used pens after 30 days even if dose remains.

Can I use Victoza if I do not have diabetes? Victoza is FDA-approved only for type 2 diabetes (in adults and children 10 and older) and to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Liraglutide at a higher dose (3.0 mg per day) is approved for chronic weight management under a different brand name; that product is not Victoza and should not be substituted.

What is the difference between Victoza and other GLP-1s? Victoza is the only daily GLP-1 still in wide U.S. use. Most newer agents (semaglutide, tirzepatide, dulaglutide) are once-weekly. The active molecule, liraglutide, is the same in Victoza and the higher-dose weight-management product, but the labels and dose ranges differ.

Does Victoza help with weight loss? Yes, modestly. Mean weight loss in LEAD trials at 1.2 mg was 2.0 to 2.5 kg over 26 weeks, and at 1.8 mg about 2.5 to 3.2 kg. This is less than the weight loss seen with higher-dose liraglutide products approved specifically for weight management or with semaglutide and tirzepatide.

Can I use Victoza with insulin? Yes, with monitoring. Combination therapy is FDA-approved. Hypoglycemia risk increases when GLP-1 agents are added to insulin or sulfonylureas, so insulin doses are typically reduced when Victoza is started, particularly basal insulin doses.

What should I do before surgery? Per the American Society of Anesthesiologists 2023 guidance, hold daily liraglutide for at least 24 hours before elective surgery requiring sedation. Discuss timing with your surgeon and anesthesiologist. Resume after surgery once oral intake has normalized.

Related guides

• What Is Liraglutide? The Daily GLP-1 Behind Victoza and Saxenda, Explained
• Victoza Dosing: Complete Guide to Liraglutide Injection Schedule and Titration
• Metformin 1000 mg Twice Daily: What This Dose Does and Who It's For
• What Is the Maximum Daily Dose of Metformin? FDA Limits, Safety Thresholds, and When Higher Doses Stop Working
• How Much Does Compounded Tirzepatide Cost in 2026? A Dose-by-Dose Pricing Guide and Decision Framework
• When to Increase Tirzepatide Dose: The Clinical Decision Framework for Safe Escalation
• Tool: dosage calculator

Sources

1. Novo Nordisk Victoza (liraglutide) prescribing information, current revision.
2. Marso et al., LEADER cardiovascular outcomes trial, NEJM, 2016.
3. Garber et al., LEAD-3 monotherapy trial, Lancet, 2009.
4. Nauck et al., LEAD-2 metformin add-on trial, Diabetes Care, 2009.
5. Russell-Jones et al., LEAD-5 with insulin glargine, Diabetologia, 2009.
6. Capehorn et al., SUSTAIN-10 head-to-head semaglutide vs liraglutide 1.2 mg, Diabetes Metab, 2020.
7. American Diabetes Association Standards of Medical Care in Diabetes, 2025 update.
8. American Society of Anesthesiologists 2023 consensus on perioperative management of GLP-1 receptor agonists.
9. FDA Adverse Event Reporting System (FAERS) liraglutide query, 2024 dataset.
10. Tamborlane et al., ELLIPSE pediatric type 2 diabetes liraglutide trial, NEJM, 2019.
11. Nauck et al., long-term liraglutide safety and tolerability pooled analysis, Diabetes Obes Metab, 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Victoza is a registered trademark of Novo Nordisk A/S. All other brand names are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.